Kevin T. Conroy President and Chief Executive Officer
Kevin T. Conroy was named President and Chief Executive Officer of Exact Sciences in April 2009. He also serves as a Director. In December 2005, he was appointed President and Chief Executive of Third Wave, and served in that position until the company's acquisition by Hologic in July 2008. He joined Third Wave in July 2004 and served as the company's general counsel until December 2005. Prior to joining Third Wave, Conroy served as Intellectual Property counsel at GE Healthcare. Before joining GE Healthcare, Conroy was Chief Operating Officer of two early stage, venture-backed technology companies in Northern California. Prior to those positions, he was an Intellectual Property litigator at two Chicago law firms: McDermott Will & Emery; and Pattishall, McAuliffe, Newbury, Hilliard and Geraldson, where he was a partner. He earned a Bachelor of Science degree in electrical engineering from Michigan State University, as well as a law degree from the University of Michigan Law School.
Graham P. Lidgard Chief Science Officer
Graham P. Lidgard, Ph.D., was appointed Chief Science Officer of Exact Sciences in August 2009. Dr. Lidgard led the research and development organization at Gen-Probe Inc. that developed that company's Procleix blood screening products and Aptima sexually transmitted disease products. Dr. Lidgard also created and led the system development group at Gen-Probe that developed its fully automated Tigris system. Prior to joining Gen-Probe, Dr. Lidgard was co-founder and Vice President of product development of Matritech Inc., a Cambridge, Massachusetts-based developer of diagnostic products for the early detection of bladder cancer. Before he co-founded Matritech, Dr. Lidgard held senior positions at Ciba Corning Diagnostics Corp.'s worldwide diagnostics group. While at Ciba Corning, he was involved in the development of more than 70 510(k)-cleared products. He led the program for the development of the magnetic particle chemiluminescent technology that became the ACS:180 and Centaur systems. Dr. Lidgard joins Exact Sciences from Nanogen Inc., where he was Senior Vice President of research and development. Dr. Lidgard earned a Bachelor's degree with honors and a Doctorate in biological chemistry from the University of Manchester in England.
Maneesh K. Arora Senior Vice President and Chief Financial Officer
Maneesh K. Arora was appointed Senior Vice President and Chief Financial Officer of Exact Sciences in April 2009. Arora took on the additional role of Chief Operating Officer in February 2012. Prior to joining Exact Sciences, Arora served as Chief Financial Officer of Third Wave Technologies, a molecular diagnostic company focused on cervical cancer screening, from January 2006 until the company's acquisition by Hologic in July 2008. He joined Third Wave in January 2003 as Director of Strategy and was promoted successively to Vice President and Senior Vice President in 2004. He began his career at Kraft Foods as a financial analyst and held several positions of increasing responsibility during his nine years there. Arora earned a Bachelor's degree in economics from the University of Chicago and a Master of Business Administration from the Kellogg Graduate School of Management.
For investigational use only. The performance characteristics of this product have not been established. Certain statements contained in this website, other than historical information, consist of forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and are subject to a variety of risks and uncertainties that could cause actual results to differ materially from the results contemplated thereby. Any forward-looking statements we make should be considered in light of the risks and uncertainties described in our filings with the Securities and Exchange Commission, including but not limited to those described in our most recent Form 10-K and subsequent Forms 10-Q. We undertake no obligation to update or revise the information provided herein, whether as the result of new information, future events or circumstances or otherwise.